Results 181 to 190 of about 55,945 (286)

Effective Treatment With Olanzapine for Burning Mouth Syndrome With Denture Intolerance in an Older Patient: A Case Report

open access: yesGerodontology, EarlyView.
ABSTRACT Introduction Burning mouth syndrome (BMS) is occasionally accompanied by denture intolerance. Case Presentation An 80‐year‐old woman with complaints of residual and relapsed intraoral pain and denture intolerance due to BMS was improved by olanzapine without severe adverse events, and her eating ability was successfully restored.
Motoko Watanabe   +7 more
wiley   +1 more source

First successful protocol for desensitization to eptinezumab

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed
Benoit Gerard   +8 more
wiley   +1 more source

Apoptosis of Human T-Cell Acute Lymphoblastic Leukemia Cells by Diphenhydramine, an H1 Histamine Receptor Antagonist

open access: hybrid, 2004
Shawkat-Muhialdin Jangi   +7 more
openalex   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly   +17 more
wiley   +1 more source

Investigation of the Pathomechanism of Chronic Cough Using an In Vitro Approach

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 247-249, March 2025.
Umesh Singh, Jonathan A. Bernstein
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

Very Long‐Term Stability of Tryptase in Frozen Serum Samples

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 276-277, March 2025.
Florent Broussal   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy